rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    STOK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Stoke Therapeutics to Present at Upcoming Investor Conferences in November
      Nov 3Yahoo FinanceSTOK
      Stoke Therapeutics (STOK) Stock Price Faces Q3 Results Cash Burn Question
      Oct 31Yahoo FinanceSTOK
      Stoke Therapeutics Inc (STOK) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Phase 3 ...
      Oct 31Yahoo FinanceSTOK
      Stoke Therapeutics, Inc. Q3 2026 Earnings Call Summary
      Oct 30Yahoo FinanceSTOK
      Goldman Sachs lowers Stoke Therapeutics price target on expenses
      Oct 30Investing.comSTOK
      Stoke Therapeutics Q3 Earnings Call Highlights
      Oct 30Yahoo FinanceSTOK
      Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates
      Oct 29Yahoo FinanceSTOK
      Stoke Therapeutics Q3 2026 Earnings Call Transcript
      Oct 29BenzingaSTOK
      Earnings call transcript: Stoke Therapeutics posts revenue beat in Q3 2026
      Oct 29Investing.comSTOK
      Stoke Therapeutics earnings missed by $0.15, revenue topped estimates
      Oct 29Investing.comSTOK
      Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

      BEDFORD, Mass., October 29, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the third quarter ended September 30, 2026, and provided business updates including progress of the global

      Oct 29Yahoo FinanceSTOK
      Stoke Therapeutics earnings: Investors brace for revenue test By Investing.com
      Oct 29Investing.comSTOK
      Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2026 Business and Financial Updates
      Oct 22Yahoo FinanceSTOK
      Stoke Therapeutics: The Market Misread A Key FDA Win (NASDAQ:STOK)

      Explore Stoke Therapeutics (STOK) ahead of the 2027 zorevunersen Dravet readout—cash runway to 2028, FDA endpoint edge, and upside valuation.

      Oct 19Seeking AlphaSTOK
      Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      BEDFORD, Mass., October 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com

      Oct 16Yahoo FinanceSTOK
      Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and AbbVie (ABBV)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Oct 13The Globe and MailSTOK
      Stoke therapeutics CMO Barry Ticho sells $27,493 in stock
      Oct 13Investing.comSTOK
      Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock
      Oct 13Investing.comSTOK
      Stoke Therapeutics presents data on ADOA treatment STK-002
      Oct 12Investing.comSTOK
      Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
      Oct 12Yahoo FinanceSTOK
      FDA Alignment on Zorevunersen Endpoints Could Be A Game Changer For Stoke Therapeutics (STOK)
      Oct 9Yahoo FinanceSTOK
      Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (STOK) and Compugen (CGEN)

      Tipranks Press Release.

      Oct 7The Globe and MailCGENSTOK
      Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
      Oct 6Yahoo FinanceSTOK
      Stoke Therapeutics aligns with FDA on zorevunersen NDA submission
      Oct 5Investing.comSTOK
      Stoke Therapeutics Completes FDA Meeting on Planned Zorevunersen NDA

      Stoke Therapeutics (STOK) said Monday it has completed a successful meeting with the US Food and Dru

      Oct 5Yahoo FinanceSTOK
      Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

      BEDFORD, Mass., October 05, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the U.S. Food and Drug Administration (FDA) intended to align on key aspects of the

      Oct 5Yahoo FinanceSTOK
      Stoke Therapeutics appoints Bo Cumbo to board of directors
      Sep 23Investing.comSTOK
      Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

      BEDFORD, Mass., September 16, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock to

      Sep 16Yahoo FinanceSTOK
      Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence
      Sep 10Investing.comSTOK
      Stoke Therapeutics at Cantor conference: dravet data, cash runway
      Sep 9Investing.comSTOK
      Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

      –4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zore

      Sep 3Yahoo FinanceSTOK
      Stoke Therapeutics to Present at the Cantor Global Healthcare Conference

      BEDFORD, Mass., September 02, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare

      Sep 2Yahoo FinanceSTOK
      Stoke, Biogen present 4-year zorevunersen data for Dravet syndrome
      Sep 1Investing.comBIIBSTOK
      Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)

      BEDFORD, Mass. & CAMBRIDGE, Mass., September 01, 2026--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today announced presentations of data at the 16th European Epilepsy Congress (EEC), taking place September 5-9 in Athens, Greece. These data support the potential of zorevunersen as a first-in-class disease-modifying treatment for Dravet syndrome. The g

      Sep 1Yahoo FinanceBIIBSTOK
      Dravet Syndrome Market Trends Indicate Sustained Growth During the Forecast Period (2026–2036), Driven by Novel Treatment Approaches | DelveInsight

      The Dravet syndrome market is poised for steady growth, driven by increasing disease awareness, earlier genetic diagnosis, and the expanding adoption of targeted anti-seizure therapies. The introduction of innovative treatments, including Zorevunersen (STK-001) (Stoke Therapeutics and Biogen), Bexicaserin (LP352) (Lundbeck), Clemizole Hydrochloride (EPX-100) (Harmony Biosciences), ETX101 (Encoded Therapeutics), and others, is expected to improve patient outcomes and expand the treatment landscap

      Aug 24Yahoo FinanceSTOK
      Stoke Therapeutics shares rise as JPMorgan starts coverage with Overweight rating

      Stoke Therapeutics (NASDAQ:STOK) shares gained 1. 4% in pre-market trading after JPMorgan initiated coverage of the biotechnology company with an Overweight rating and a $40 price target, adding another positive Wall Street view to the outlook for the RNA-focused drug developer.

      Aug 21Yahoo FinanceSTOK
      Why is Stoke Therapeutics stock gaining today?
      Aug 21Investing.comSTOK

      This is the newest page. Registered accounts read further back.